Roche also announced first-quarter sales shrank 1%.
Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.
The FDA issued an official halt, five days after Halozyme stopped the Phase-II trial because of patient stroke information.
Analyses by Jefferies indicate that although doctors are interested in the experimental anti-cholesterol drugs, CV data will be a critical differentiator.
The drugmaker halted Phase III trials of a three-month medication based on good efficacy feedback.
The company says it will continue to test its MAGE-A3 cancer drug among a subset of non-small cell lung cancer patients and among melanoma patients.
A working group set out parameters for what counts as a meaningful outcome for pancreatic, breast, lung and colon cancer clinical trials.
PhRMA and the National Minority Quality Forum's "I'm In" campaign seeks to tackle clinical trial diversity (or the lack thereof).
Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.
Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.
Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.
The drugmaker announced Tuesday that it will pursue a Phase-III Yervoy-nivolumab study.
Roche said an onartuzumab and Tarceva mix did not help advanced non-small cell lung cancer patients with MET-positive tumors.
The drugmaker said JAK inhibitor GSK2586184 showed no effect in Phase II and has put an ulcerative colitis test on hold.
The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.
Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.
The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.
TapTrak seeks to apply behavioral tracking to clinical trials.
A sealed complaint, reported on by the Wall Street Journal, builds on concerns that were already surrounding the now-controversial Plato study.
The school will act as an independent panel for the drug maker, reviewing requests from investigators for access to anonymized, clinical-trial data.
A clinical trial shows that using Xtandi before chemotherapy—Zytiga's indication—improves progression-free survival.
The US agency says we've got too much data that cannot be reproduced.
Additional studies of bitopertin, which is meant to target the condition's negative symptoms, are ongoing.
Merck and Celgene are exploring a combination that could solidify their immuno-oncology footholds.
Mid-stage data show the drug, romosozumab, was associated with significant increases in bone mineral density compared to Lilly's Forteo and off-patent Fosamax.
The American College of Cardiology is contributing its Pinnacle registry to identify clinical trial patients.
A recent poll shows a strong desire among web-savvy patients to play a more active role in medical research.
Vaccine LU AF20513 is the their third Alzheimer's collaboration.
The drug failed to hit its Phase III targets.
Phase-IIIb study results indicate Lyxumia—which is approved abroad but not in the US—was "non-inferior" in terms of controlling blood sugar levels regardless of whether the shot was given before breakfast or later.